– Transaction creates new joint-venture in the North American produce industry backed by private investment firms – – Parties intend to provide additional capital to execute a roll-up strategy of other produce assets and operations – LAKE MARY, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Vanguard Food LP, a privately-held produce industry joint venture between Kennedy Lewis Investment Management, Sweat Equities, and Village Farms International, today announced the closing of a transaction which created a new, e ...

Orlando, FL, June 02, 2025 (GLOBE NEWSWIRE) -- Coda Octopus Group, Inc. (“CODA” or the “Company”) (NASDAQ: CODA), a global market leader in real-time 3D/4D/5D and 6D imaging sonar technology for real-time subsea intelligence and new generation augmented reality diving technology, will host a conference call on Monday, June 16, 2025 at 10:00 a.m. Eastern time to discuss its results for its fiscal second quarter ended April 30, 2025 (“SQ2025”). A press release detailing these results will be issued before the ...

– Closing of transaction places Company in net cash position, poised for leadership in global cannabis industry – – Company plans to file proforma financial statements excluding discontinued operations within four business days – VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) today announced that its pending transaction to privatize the majority of its fresh produce business closed on May 30, 2025. The transac ...

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Asante Gold Corporation (CSE: ASE | GSE: ASG | FRANKFURT:1A9 | U.S.OTC: ASGOF) (“Asante” or the “Company”) is pleased to announce that it has received the second US$100 million advance from Fujairah Holdings LLC (the “Second Advance”), as scheduled under the Gold Forward Agreement (the “Gold Forward Agreement”) described in the Company’s news release of December 19, 2024. Asante has also secured a US$10 million bridge loan facility (the “Bridge ...

Study met its primary endpoint by achieving statistical significance on one of its two pre-specified co-primary endpoints, demonstrating increased electrical connectivity between the brain and hand muscle in individuals with a cervical level spinal cord injury (SCI).Study also showed a positive trend in the secondary endpoint evaluating change in “GRASSP” score, a measure designed specifically to assess hand function in people with cervical injuries.As the first pharmaceutical candidate to show improved mot ...

Core Insights - BioCryst Pharmaceuticals announced new data on ORLADEYO (berotralstat) for hereditary angioedema (HAE) treatment to be presented at the EAACI meeting in Glasgow from June 13 to 16, 2025 [1][2][3] Group 1: Presentation Details - Four abstracts will be presented at the EAACI meeting, including a pooled analysis of the APeX-2 and APeX-J trials focusing on the impact of berotralstat on quality of life for HAE patients [1] - A focus group study reported positive perceptions from patients following berotralstat treatment [2] - Interim results from the APeX-P study indicated that berotralstat use reduced the number of HAE attacks requiring treatment in pediatric patients [3] Group 2: Product Information - ORLADEYO (berotralstat) is the first oral therapy specifically designed to prevent HAE attacks in patients aged 12 years and older, functioning as a plasma kallikrein inhibitor [4][5] - The recommended dosage is one capsule per day, with caution advised for dosages higher than 150 mg due to potential QT prolongation [6][7] - The safety and effectiveness of ORLADEYO in pediatric patients under 12 years have not been established, and there is limited data on its use during pregnancy [9][10] Group 3: Company Overview - BioCryst Pharmaceuticals is a global biotechnology company focused on improving the lives of individuals with hereditary angioedema and other rare diseases, utilizing structure-guided drug design for developing therapeutics [11]

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, June 2, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the 2025 Jefferies Global Healthcare Conference. 2024 Jefferies Global Healthcare ConferenceFir ...

Core Insights - Regeneron Pharmaceuticals announced interim results from the Phase 2 COURAGE trial, showing that approximately 35% of weight loss from semaglutide was due to lean mass loss, and combining it with trevogrumab helped preserve lean mass while increasing fat loss [1][2][3] Group 1: Trial Results - The COURAGE trial demonstrated that combining semaglutide with trevogrumab, with or without garetosmab, preserved 50%-80% of lean mass compared to semaglutide alone while enhancing fat mass loss [1][2] - At the 26-week interim analysis, patients receiving semaglutide alone lost an average of 7.9 lbs of lean mass, while those on the lower-dose and higher-dose combinations lost 3.7 lbs and 4.2 lbs respectively, and the triplet group lost only 2.0 lbs [3][4] - Fat mass loss was significantly higher in combination groups, with the triplet group losing an average of 25.4 lbs, representing an 84.4% change from baseline [3][4] Group 2: Safety and Tolerability - The combination therapies were generally well-tolerated, but the triplet combination had a higher rate of treatment discontinuation due to tolerability issues, with 28.3% of participants discontinuing treatment [1][6] - The overall incidence of treatment-emergent adverse events (TEAEs) was 64.9% for semaglutide monotherapy, increasing to 77.2% in the triplet group [6] Group 3: Future Directions - The full data set from the COURAGE trial is expected to be available later this year, which will provide further insights for optimizing dosing regimens in future trials [2] - Regeneron is focused on developing treatments that improve the quality of weight loss by preserving muscle mass during weight reduction, addressing a significant concern in obesity management [7][8]

Mediatiedote 2.6.2025 klo 14.00 Lassila & Tikanojan kuormalavojen korjaus- ja kierrätysliiketoiminta kasvaa Stena Recyclingin kuormalavaliiketoiminnan liiketoimintakaupan myötä 2.6.2025 alkaen Lassila & Tikanoja allekirjoitti 16.10.2024 sopimuksen Stena Recycling Oy:n kuormalavojen korjaus-, vuokraus- ja myyntiliiketoiminnan ostamisesta. Kilpailu- ja kuluttajavirasto hyväksyi liiketoimintakaupan 16.5.2025. 2.6.2025 toteutetulla kaupalla Stena Recycling Oy:n kuormalavaliiketoiminta siirtyy L&T Ympäristöp ...

ISS concludes that Apollo “has not presented a compelling case for change”TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that Institutional Shareholder Services (“ISS”) published a report on May 30, 2025 (the “ISS Report”) recommending that MediPharm shareholders vote the GREEN Proxy or voting instruction form FOR the Company’s nominees ...